Both low and high serum ferritin levels predict mortality risk in hemodialysis patients without inflammation

Clinical and Experimental Nephrology

Volumn 21, Issue 4, 2017, Pages 685-693

  Shoji, Tetsuo ^a   Niihata, Kakuya ^b,c   Fukuma, Shingo ^b,d   Fukuhara, Shunichi ^c,d   Akizawa, Tadao ^e   Inaba, Masaaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Institute for Health Outcomes and Process Evaluation Research   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular disease (CVD); Cohort; Ferritin; Hemodialysis; Mortality

Indexed keywords

ANTIANEMIC AGENT; C REACTIVE PROTEIN; FERRITIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN; ALB PROTEIN, HUMAN; BIOLOGICAL MARKER; HUMAN SERUM ALBUMIN;

ADULT; ADVERSE OUTCOME; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFLAMMATION; IRON THERAPY; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY RISK; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; SERUM; SYSTEMIC DISEASE; BLOOD; CAUSE OF DEATH; COMPARATIVE STUDY; DOWN REGULATION; HOSPITAL MORTALITY; JAPAN; KIDNEY DISEASE; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UPREGULATION;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DOWN-REGULATION; FEMALE; FERRITINS; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; INFLAMMATION; JAPAN; KIDNEY DISEASES; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS; SERUM ALBUMIN, HUMAN; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84981287647     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-016-1317-1     Document Type: Article

References (28)

1. Kalantar-Zadeh K, Don BR, Rodriguez RA, Humphreys MH. Serum ferritin is a marker of morbidity and mortality in hemodialysis patients. Am J Kidney Dis. 2001;37(3):564–72.
2. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16(10):3070–80.
3. Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, et al. Understanding the recent increase in ferritin levels in United States dialysis patients: potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing. Clin J Am Soc Nephrol. 2015;10(10):1814–21.
4. Hasuike Y, Nonoguchi H, Tokuyama M, Ohue M, Nagai T, Yahiro M, et al. Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study. Clin Exp Nephrol. 2010;14(4):349–55.
5. Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, et al. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86(4):845–54.
6. Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44(1):94–111.
7. Park KS, Ryu GW, Jhee JH, Kim HW, Park S, Lee SA, et al. Serum ferritin predicts mortality regardless of inflammatory and nutritional status in patients starting dialysis: a prospective cohort study. Blood Purif. 2015;40(3):209–17.
8. Kawaguchi T, Tong L, Robinson BM, Sen A, Fukuhara S, Kurokawa K, et al. C-reactive protein and mortality in hemodialysis patients: the dialysis outcomes and practice patterns study (DOPPS). Nephron Clin Pract. 2011;117(2):c167–78.
9. Bazeley J, Bieber B, Li Y, Morgenstern H, de Sequera P, Combe C, et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(10):2452–61.
10. Young EW, Goodkin DA, Mapes DL, Port FK, Keen ML, Chen K, et al. The dialysis outcomes and practice patterns study (DOPPS): an international hemodialysisstudy. Kidney Int. 2000;57(Suppl 74):S74–81.
11. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, Wolfe RA. The dialysis outcomes and practice patterns study (DOPPS): design, data elements, and methodology. Am J Kidney Dis. 2004;44(5 Suppl 2):7–15.
12. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, et al. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010;14(3):240–75.
13. KDOQI, National Kidney Foundation. KDOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11–145.
14. Fouque D, Kalantar-Zadeh K, Kopple J, Cano N, Chauveau P, Cuppari L, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73(4):391–8.
15. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.
16. Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2005). Ther Apher Dial. 2007;11(6):411–41.
17. Kirkali Z, Guzelsoy M, Mungan MU, Kirkali G, Yorukoglu K. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume. Urol Int. 1999;62(1):21–5.
18. Kalousova M, Krechler T, Jachymova M, Kubena AA, Zak A, Zima T. Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study. Tumour Biol. 2012;33(5):1695–700.
19. Puntarulo S. Iron, oxidative stress and human health. Mol Asp Med. 2005;26(4–5):299–312.
20. Nakanishi T, Hasuike Y, Otaki Y, Nanami M, Kuragano T. Dysregulated iron metabolism in patients on hemodialysis. Contrib Nephrol. 2015;185:22–31.
21. Harada T, Baba M, Torii I, Morikawa S. Ferritin selectively suppresses delayed-type hypersensitivity responses at induction or effector phase. Cell Immunol. 1987;109(1):75–88.
22. Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, et al. Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ. 2003;326(7399):1124.
23. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, et al. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomized controlled trial. BMC Med. 2012;10:8.
24. Kutner N, Zhang R, Johansen K, Bliwise D. Associations among nocturnal sleep, daytime intradialytic sleep, and mortality risk in patients on daytime conventional hemodialysis: US Renal Data System special study data. Hemodial Int. 2013;17(2):223–9.
25. Koyama H, Fukuda S, Shoji T, Inaba M, Tsujimoto Y, Tabata T, et al. Fatigue is a predictor for cardiovascular outcomes in patients undergoing hemodialysis. Clin J Am Soc Nephrol. 2010;5(4):659–66.
26. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int. 2008;74(8):994–7.
27. Monda KL, Joseph PN, Neumann PJ, Bradbury BD, Rubin RJ. Comparative changes in treatment practices and clinical outcomes following implementation of a prospective payment system: the STEPPS study. BMC Nephrol. 2015;16:67.
28. Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy Guideline for renal anemia in chronic kidney disease. J Jpn Soc Dial Ther. 2016;49(2):89–158 (in Japanese).